ICU Medical, Inc. (NASDAQ:ICUI) Receives Consensus Rating of “Moderate Buy” from Brokerages

ICU Medical, Inc. (NASDAQ:ICUI) has received a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $173.00.

Several equities analysts recently weighed in on the stock. Jefferies Financial Group started coverage on shares of ICU Medical in a report on Monday, October 14th. They set a “hold” rating and a $183.00 target price on the stock. KeyCorp boosted their price objective on ICU Medical from $198.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 13th. StockNews.com upgraded ICU Medical from a “hold” rating to a “buy” rating in a research note on Wednesday. Raymond James boosted their price target on ICU Medical from $158.00 to $190.00 and gave the stock an “outperform” rating in a research report on Thursday, September 12th. Finally, Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a report on Wednesday, November 13th.

ICU Medical Trading Down 0.2 %

Shares of ICUI stock opened at $168.46 on Monday. The company has a quick ratio of 1.03, a current ratio of 2.29 and a debt-to-equity ratio of 0.75. ICU Medical has a fifty-two week low of $83.26 and a fifty-two week high of $196.26. The firm’s 50 day moving average price is $176.22 and its two-hundred day moving average price is $145.10. The stock has a market cap of $4.12 billion, a price-to-earnings ratio of -36.86 and a beta of 0.66.

Insider Buying and Selling at ICU Medical

In other news, VP Daniel Woolson sold 2,502 shares of the firm’s stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the completion of the sale, the vice president now owns 13,107 shares of the company’s stock, valued at approximately $2,139,324.54. This trade represents a 16.03 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $178.46, for a total transaction of $2,141,520.00. Following the completion of the sale, the chief executive officer now directly owns 104,593 shares in the company, valued at $18,665,666.78. This represents a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 38,502 shares of company stock worth $6,573,496 in the last 90 days. 6.70% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ICU Medical

A number of hedge funds have recently bought and sold shares of ICUI. Vanguard Group Inc. lifted its holdings in ICU Medical by 0.5% during the 1st quarter. Vanguard Group Inc. now owns 2,452,720 shares of the medical instruments supplier’s stock worth $263,226,000 after buying an additional 11,991 shares during the last quarter. State Street Corp raised its position in shares of ICU Medical by 9.3% during the 3rd quarter. State Street Corp now owns 907,607 shares of the medical instruments supplier’s stock valued at $165,384,000 after acquiring an additional 77,506 shares in the last quarter. Geode Capital Management LLC lifted its stake in ICU Medical by 9.6% during the third quarter. Geode Capital Management LLC now owns 546,954 shares of the medical instruments supplier’s stock worth $99,687,000 after purchasing an additional 48,106 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in ICU Medical by 21.7% in the second quarter. Dimensional Fund Advisors LP now owns 311,542 shares of the medical instruments supplier’s stock worth $36,996,000 after purchasing an additional 55,588 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in ICU Medical by 10.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 301,107 shares of the medical instruments supplier’s stock valued at $54,868,000 after purchasing an additional 27,927 shares during the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.